PharmaEssentia’s Besremi Receives Approval for Polycythemia Vera Treatment in China
PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1), a biopharmaceutical company based in Taiwan, has announced that...
PharmaEssentia
PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development
Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s...
Nona Biosciences Partners with PharmaEssentia for Harnessing Harbor Mice Technology
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...
PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of...